# Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

> **NCT01257048** · EARLY_PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 34 (actual)

## Conditions studied

- COPD Method Evaluation
- Chronic Obstructive Pulmonary Disease Method Evaluation

## Interventions

- **DRUG:** Formoterol Turbuhaler
- **DRUG:** Budesonide/Formoterol Turbuhaler
- **DRUG:** Formoterol Turbuhaler

## Key facts

- **NCT ID:** NCT01257048
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257048, "Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01257048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*